Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)

11.35
BATS BZX Real-Time Price
As of 10:46am ET
 +0.25 / +2.25%
Today’s Change
7.36
Today|||52-Week Range
16.68
-3.57%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$702.5M

Company Description

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Contact Information

Kiniksa Pharmaceuticals Ltd.
100 Hayden Avenue
Lexington Massachusetts 02421
P:(781) 431-9100
Investor Relations:
(339) 970-9437

Employees

Shareholders

Other institutional57.13%
Mutual fund holders35.11%
Individual stakeholders15.02%

Top Executives

Sanj K. PatelChairman & Chief Executive Officer
Eben P. TessariChief Operating Officer & Senior Vice President
Mark RagosaChief Financial Officer & Senior Vice President
John F. PaoliniChief Medical Officer & Senior Vice President
Chad MorinChief Compliance Officer & Vice President